Gilead Sciences, Inc. vs Wheaton Precious Metals Corp — how do they compare? Gilead Sciences, Inc. trades at $149 (market cap $182.40B), while Wheaton Precious Metals Corp trades at $138.28 (market cap $61.17B). The key difference: Gilead Sciences, Inc. is far larger — about 3× Wheaton Precious Metals Corp's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Wheaton Precious Metals Corp for 66 Days on average.
| GILD | WPM | |
|---|---|---|
Market Cap | $182.40B | $61.17B |
Volume | 4,469,821 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $165.72 |
52-Week Low | $116.74 | $94.37 |
Typical Hold Time | 111 Days | 66 Days |
Enterprise Value | $205.46B | $63.05B |
Dividend Yield | 2.23% | 0.58% |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Wheaton Precious Metals (WPM) trades at $133.69, down 2.88% on the day, amid a bearish technical signal. The company reported record H1 2026 revenues and beat EPS estimates for three consecutive quarters, with strong profitability margins (gross margin 75.25%, net margin 64.66%). Recent news highlights a growth strategy targeting 1.2 million ounces of production by 2030 through an expanded deal pipeline, supported by a fully funded capital plan.
The outlook remains positive given robust earnings momentum and analyst consensus (80% buy ratings, $164.80 price target). Key risks include execution of growth targets and sensitivity to gold/silver prices. The stock offers exposure to precious metals with high margins but trades at premium valuations (P/E 29.94, P/S 19.36), requiring confidence in delivery of projected growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →